Shop Talk

View at publisher Summarise with VIRAT

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

George Coukos, MD, PhD, Establishes New Laboratory at Weill Cornell Medicine George Coukos, MD, PhD, a physician-scientist and international authority on tumor immunology and cellular immunotherapy, joined Weill Cornell Medicine to lead the new Ludwig Laboratory for Cell Therapy. He previously was Founding Director of the Ludwig Lausanne Branch in Switzerland.George Coukos, MD, PhDCoukos joins Weill Cornell's faculty as Professor of Immunology in Medicine, with a secondary appointment in the Department of Pathology and Laboratory Medicine. In addition to leading the laboratory, he will serve as Associate Director for Cell Therapy at the Meyer Cancer Center, where he will oversee a multidisciplinary team to develop next-generation T-cell therapies and analyze their clinical translation. “George is one of the world's foremost experts in cell therapies, an area of science that holds enormous promise for cancer treatment and care,” said Jedd Wolchok, MD, PhD, the Meyer Director of the Meyer Cancer Center and Director of the Ludwig Collaborative Laboratory at Weill Cornell. “His recruitment to our institution lands us in rarified air for cutting-edge cell therapy.” Leonard Zon, MD, Wins 2026 March of Dimes Richard B. Johnston Jr., MD Prize Leonard Zon, MD, is the winner of the 2026 March of Dimes Richard B. Johnston Jr., MD Prize for his work in developmental biology. Zon's pioneering work has illuminated how blood develops in embryos, leading to a deeper understanding of rare blood diseases, including in pregnancy, and breakthrough treatments for genetic blood disorders affecting babies and children.Leonard Zon, MDThe March of Dimes Richard B. Johnston Jr., MD Prize recognizes scientists whose work in developmental biology has transformed our understanding of human health. Zon's use of developmental biology to illuminate how blood forms in embryos exemplifies this mission, with direct applications to pregnancy complications and childhood diseases. “Ever since my first experience working with leukemia patients early in my research career, I've been trying to uncover the mysteries of blood to help those affected by blood and other diseases,” said Zon. “So, to be instrumental in the discovery of new pathways that underscore blood development in embryos and to have a real impact on diseases affecting kids and babies, that's priceless. And to do it with the fascinating zebrafish and be honored for it is icing on the cake.” Grace Taylor, MBA, Named President of UCHealth Greeley Hospital Grace Taylor, MBA, a key leader in northern Colorado's health care landscape for nearly 20 years, has been named President of UCHealth Greeley Hospital.Grace Taylor, MBASince 2019, Taylor has served as Vice President of Operations for UCHealth's Poudre Valley Hospital in Fort Collins and Medical Center of the Rockies in Loveland. During the COVID-19 pandemic, she frequently served as incident commander for both hospitals, ensuring the continued delivery of exceptional care while prioritizing patient and staff safety. In recent years, she has overseen major expansion projects at both hospitals. “I am honored to join this remarkable hospital and contribute meaningfully to the health and well-being of the Greeley and Weld County communities,” Taylor said. “I look forward to learning from and working alongside this talented team to help shape a future that reflects our shared commitment to delivering the highest quality care.” Charles Swanton, MB, PhD, Awarded Sjöberg Prize for Describing Tumors' Evolution Charles Swanton, MB, PhD, FRCP, FMedSci, FAACR, FRS, is winner of the Sjöberg Prize for discoveries concerning clonal evolution of cancer cells and its importance for tumor growth and metastasis.Charles Swanton, MB, PhDThe Sjöberg Prize is awarded in partnership between the Royal Swedish Academy of Sciences and the Sjöberg Foundation. It is awarded to a person or persons who have made decisive contributions to cancer research. Charlie has been recognized for his contribution to the fundamental understanding of tumor evolution. As part of the Cancer Research UK funded TRACERx and TRACERx EVO studies, his team has traced the development of lung tumors from the point of diagnosis, to interrogate the biology behind disease evolution, drug resistance, cancer spread, and immune evasion. “I hope this prize money is going to allow us to really understand how that very first step in tumor initiation and evolution occurs. If we can understand that process, I hope we can intercept it and prevent it from happening and therefore prevent cancers from emerging,” he said. Carl June, MD, & Michel Sadelain, MD, PhD, Earn The Frontiers of Knowledge Award The BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine has gone to Carl June, MD, Richard W. Vague Professor in Immunotherapy at University of Pennsylvania, and Michel Sadelain, MD, PhD, Director of the Columbia Initiative in Cell Engineering and Therapy at Columbia University, for revolutionizing the treatment of cancer by means of CAR-T cell immunotherapy. The two laureates pioneered an innovative therapeutic strategy whereby T cells are extracted from the patient's own immune system, grown in the lab, and genetically engineered so they recognize and selectively destroy cancer cells on being infused back into the body, leading to remission of the disease.Carl June, MDMichel Sadelain, MD, PhDJune and Sadelain's “complementary studies” on CAR-T cells, on the path from basic research to clinical application, have driven the development of “therapeutics for the treatment of patients with blood cancers like leukemia,” which have already benefited “tens of thousands of individuals, including many children,” said the committee in its citation. “Thousands of laboratories around the world, including mine, are striving to make CAR-T cells work in solid cancers, and I think we'll eventually see major progress,” June said. Sadelain concured: “I believe there's every reason to be optimistic that in the next few years, certainly the next decade, we will have effective CAR T-cell therapies for lung cancer, brain tumors, and others. Today, the scientific, medical, and pharmaceutical establishments are convinced of the value of engineered immunity. And now it is our job to make it work for many other cancers.” Eva Vailionis, MS, CGC, Presented With the 2026 ACMG Foundation Genetic Counselor Best Abstract Award Eva Vailionis, MS, CGC, is the 2026 recipient of the ACMG Foundation Genetic Counselor Best Abstract Award. The ACMG Foundation for Genetic and Genomic Medicine selected Vailionis based on her abstract, “Prevalence and Tumor Characteristics of Patients with TMEM127 Pathogenic Variants in a Large, Pan-Cancer Cohort.”Eva Vailionis, MS, CGCVailionis is a cancer genetic counselor at Memorial Sloan Kettering Cancer Center in New York City. She earned her master's degree in genetic counseling from Rutgers University in 2022 and practices in hereditary cancer predisposition, working alongside a large multidisciplinary team that includes genetic counselors and attending physicians. “I am honored to receive the 2026 ACMG Genetic Counselor Best Abstract Award on behalf of my Memorial Sloan Kettering Clinical Genetics team,” said Vailionis. “I am also incredibly grateful to work with a group that actively supports genetic counselors as academics, clinicians, and key contributors to genetics research and patient care. This work, and all publications from our team, would not be possible without that support. Thank you to the ACMG Foundation and its donors for recognizing the vital role of genetic counselors in advancing genetics research and health care delivery.” David Gius, MD, PhD, Named Director of the University of Cincinnati Cancer Center The University of Cincinnati Cancer Center appointed David Gius, MD, PhD, as its next Director. Gius, an internationally recognized physician-scientist and radiation oncologist, will officially begin his tenure on July 1, 2026.David Gius, MD, PhDIn addition to his role as Director, Gius will hold an academic appointment within the Department of Radiation Oncology at the UC College of Medicine. He joins the University of Cincinnati from the Mays Cancer Center at UT Health San Antonio MD Anderson, where he served as Associate Cancer Center Director for Translational Research and Assistant Dean for Research. “I'm truly honored to be entrusted with the opportunity to lead the University of Cincinnati Cancer Center,” said Gius. “The Cancer Center is a vital part of the community and plays a critical role at one of the most vulnerable moments in a person's life, when they receive a cancer diagnosis. Our ultimate goal should be to provide not just outstanding, but superlative care to each and every person in our region. If anyone in our community has an aggressive cancer, we will provide the clinical trials, experimental drugs, the newest therapies, and most importantly, hope. They should feel comfortable that our cancer center provides the best and most up-to-date care for each and every one of them.” Vinay Badhwar, MD, Elected President ofthe Society of Thoracic Surgeons The Society of Thoracic Surgeons (STS) elected Vinay Badhwar, MD, as its 62nd President during the organization's Annual Meeting in New Orleans.Vinay Badhwar, MDAn internationally recognized cardiothoracic surgeon, physician-scientist, and innovator, Badhwar brings more than two decades of clinical, research, and administrative leadership experience to the presidency. He is Executive Chair of the West Virginia University (WVU) Heart and Vascular Institute and Service Line, and Professor and Chairman of the Department of Cardiovascular and Thoracic Surgery at WVU, in Morgantown, West Virginia. During his presidential year, Badhwar will advance a three-part framework that reflects both the daily practice of cardiothoracic surgery and the mission of STS: excellence, evidence, and impact. “These are not abstract ideals; they define who we are as cardiothoracic surgeons and the enduring identity of the STS,” said Badhwar. “Excellence begins with our commitment to perform the very best operation for every patient, every time. Evidence challenges us to evolve with data and ground our decisions in science. Impact is measured not only in survival rates, but in lives restored, families preserved, and trust earned.” Anne Klibanski, MD, Elected Chair of the Massachusetts Health & Hospital Association Board of Trustees Anne Klibanski, MD, President and CEO of Mass General Brigham, has been elected as the 85th Chair of the Massachusetts Health & Hospital Association (MHA) Board of Trustees.Anne Klibanski, MDKlibanski brings extensive leadership experience and a strong commitment to patient-centered innovation to MHA's Board of Trustees. As President and Chief Executive Officer of Mass General Brigham since 2019, she has led a world-renowned healthcare system, which includes Brigham and Women's Hospital and Massachusetts General Hospital, Mass Eye and Ear, McLean, Spaulding Rehabilitation, seven community hospitals, a health insurance company, physician networks, community health centers, home-based care, and long-term care services. “Healthcare is undergoing profound change, and meeting this moment requires partnership, clarity of purpose, and a commitment to the patients and communities we serve,” said Klibanski. “I'm honored to step into the role of MHA Board Chair and to represent Mass General Brigham in this work. The integration of our system, bringing together exceptional clinicians and teams across MGB's hospitals, demonstrates what aligned, patient-centered care can achieve. Together with MHA and our colleagues statewide, we will advance research, innovation, and high-quality care for all Massachusetts residents.” Krista Curell Named President of the University of Chicago Medical Center The University of Chicago Medicine appointed Krista Curell, JD, RN, as President of the University of Chicago Medical Center, where she will lead day-to-day operations and strategy for the hub of the growing academic health system. The appointment recognizes her pivotal role in advancing operational excellence, equity, and strategic growth across the organization.Krista Curell, JD, RN“It's an absolute privilege to serve the University of Chicago Medical Center and our entire health system community in this new role,” said Curell. “Every day, I'm inspired by our teams' commitment to our patients, our mission, and each other. Together, we're expanding access to world-class care, advancing health equity, and creating an environment where innovation and compassion drive everything we do.” Share Your News! Send information on career developments and cancer center news for this column to [email protected]

Publication details

Journal / source
Oncology Times
Volume
48
Issue
4
Pages
32–33
Publication date
27 March 2026
Language
EN